European Wellness Biomedical Group Announces New Klotho Research Initiative Led by Prof. Mike Chan

"Klotho represents the next frontier in longevity medicine," said Professor Mike Chan, Chief Scientist at EWBG. "Our research aims to understand how Klotho affects aging and how we can use it to treat chronic diseases that have long been associated with aging." "Klotho represents the next frontier inlongevity medicine," saidProfessorMike Chan , Chief Scientist at EWBG. "Our research aims to understand how Klotho affects aging and how we can use it to treat chronic diseases that have...

"Klotho represents the next frontier in longevity medicine," said Professor Mike Chan, Chief Scientist at EWBG. "Our research aims to understand how Klotho affects aging and how we can use it to treat chronic diseases that have long been associated with aging."

Research Focus Areas

The new initiative will focus on three primary research areas:

This research builds on existing collaborations at EWBG, where leading scientists focus on advancing Klotho-based therapies for regenerative health.

Klotho: A Potential Breakthrough in Longevity Medicine

Klotho is gaining attention for its ability to regenerate tissues and reverse damage caused by age-related diseases. Unlike NAD+, which primarily enhances cellular metabolism and energy production, Klotho offers a broader range of therapeutic applications, including tissue regeneration, cognitive function improvement, and cardiovascular health.

As we age, Klotho levels naturally decline, leading to conditions such as cognitive decline, heart disease, and kidney failure. Research suggests that restoring Klotho levels can reverse the effects of oxidative stress, inflammation, and cellular senescence, offering new treatment possibilities for a range of age-related diseases.

Professor Mike Chan: Leading the Charge in Klotho Research

Professor Mike Chan, a leading expert in stem cell therapy and longevity medicine, is spearheading this groundbreaking initiative at EWBG. His extensive experience in bio-regenerative medicine positions him as a key figure in exploring Klotho's potential to revolutionize the treatment of age-related diseases. Through FCTI, a subsidiary of EWBG, Professor Chan and his team are developing therapies that combine stem cell technology and Klotho proteins to stimulate tissue regeneration in the brain, kidneys, and heart.

"By harnessing Klotho's regenerative properties, we hope to address chronic conditions that were previously untreatable," said Professor Chan. "Our ultimate goal is to improve quality of life and provide lasting solutions for those affected by aging-related diseases."

The Future of Klotho in Longevity Medicine

The future of Klotho-based therapies looks promising, with Professor Mike Chan and EWBG at the forefront of this innovative field. As more research is conducted, Klotho is expected to play a pivotal role in advancing longevity medicine, offering a new approach to treating aging and chronic diseases. The potential applications of Klotho are vast, from neurodegenerative disease treatment to kidney regeneration and cardiovascular health.

With strong research partnerships, significant funding, and ongoing clinical trials, Klotho is poised to become a cornerstone of longevity medicine, transforming how we approach aging and disease. Professor Mike Chan's leadership ensures that this promising protein will soon offer new hope to those seeking longer, healthier lives.

Photo - https://mma.prnewswire.com/media/2587407/Prof_Dr_Mike_Chan_talks_growing_importance_Klotho_anti_aging_medicine.jpg

Logo - https://mma.prnewswire.com/media/2362609/EW_COLOR_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/european-wellness-biomedical-group-announces-new-klotho-research-initiative-led-by-prof-mike-chan-302338980.html